Guard Therapeutics International AB (publ) (STO:GUARD)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.475
+0.175 (13.46%)
At close: Mar 27, 2026
Market Cap29.75M -85.5%
Revenue (ttm)n/a
Net Income-108.85M
EPS-6.04
Shares Out20.17M
PE Ration/a
Forward PE0.64
Dividendn/a
Ex-Dividend Daten/a
Volume27,786
Average Volume13,581
Open1.315
Previous Close1.300
Day's Range1.315 - 1.485
52-Week Range1.100 - 27.000
Beta-0.24
RSI45.39
Earnings DateMay 7, 2026

About STO:GUARD

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. The company’s pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabet... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 12
Stock Exchange Nasdaq Stockholm
Ticker Symbol GUARD
Full Company Profile

Financial Performance

Financial Statements